Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8234094 | International Journal of Radiation Oncology*Biology*Physics | 2009 | 7 Pages |
Abstract
Patients with HPV+ OPSCC have an excellent prognosis after radiochemotherapy, but cisplatin-based chemotherapy may not confer a satisfactory outcome, especially in WT cases, thereby justifying the additional or alternative use of taxanes and epidermal growth factor receptors inhibitors. Uncommon distant metastases and second tumors in the HPV+ group may be cause for clinicians to review the follow-up policies in these patients.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Carlo M.D., Federica Ph.D., Lisa M.D., Silvana M.D., Laura M.D., Paolo M.D., Ester M.D., Mauro M.D., Patrizia M.D.,